Monoclonal antibodies immunomodulators

Category Immunomodulator Monoclonal antibody Half-life 12-35 days... 

Indications Prophylaxis of serious lower respiratory tract disease caused by RSV in pediatric patients Category Immunomodulator Monoclonal antibody Half-life 18 days... 

Immunomodulators affect the functioning of the immune system. Immune functions may be promoted as well as suppressed by these agents. In this section interferon alpha, BCG, immunocyanin and aldesleukine and the monoclonal antibodies, alem-tuzumab, bevacizumab, cetuximab, trastuzumab, rit-uximab and ibritumomab tiuxetan will be briefly discussed. 

Immunomodulators (nonvaccine, nonallergenic) Growth factors, cytokines, some hormones and monoclonal antibodies intended to mobilize, stimulate, decrease, or otherwise alter the production of hematopoietic cells in vivo... 

A number of other types of drug are under development. These include agents that interfere with leukotriene synthesis (see LIPOXYGENASE inhibitors), interleukin-1 antagonists, monoclonal antibodies linked to cytotoxic drugs etc. See also IMMUNOMODULATORS. 

ND-STAT brompheniramine, nebacumab [ban, inn. usan) (HA-1A) is a monoclonal antibody (MW c. 1,000,000) that has immunomodulator/ IMMUNOSUPPRESSANT activity. It has been used for treatment of Gram-negative sepsis and septic shock. Withdrawn from European market in 1994. 

Monoclonal antibody therapy rituximab, alemtuzumab Non-specific immunotherapies and adjuvants BCG, interleukin-2 (IL-2), and interferon-a Immunomodulating drugs thalidomide and lenalidomide Cancer vaccines vaccine for advanced prostate cancer Side effects Flu-like symptoms, including fever, chills, nausea, and loss of appetite, allergic reactions, fatigue decrease in blood pressure Work better for some types of cancer than for others... 

---